J I Weitz

Summary

Publications

  1. ncbi request reprint New anticoagulants for treatment of venous thromboembolism
    Peter L Gross
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arterioscler Thromb Vasc Biol 28:380-6. 2008
  2. ncbi request reprint Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
    Jeffrey I Weitz
    Thrombosis and Atherosclerosis Research Institute, Hamilton General Hospital, Ontario, Canada
    Thromb Haemost 104:633-41. 2010
  3. ncbi request reprint Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits
    J W Yau
    Dr Jeffrey I Weitz, Thrombosis and Atherosclerosis Research Institute, David Braley Research Institute, 237 Barton St E, Hamilton, ON L8L2X2, Canada, Tel 1 905 574 8550, Fax 1 905 575 2646, E mail
    Thromb Haemost 112:79-86. 2014
  4. doi request reprint Zinc: an important cofactor in haemostasis and thrombosis
    Trang T Vu
    Thrombosis and Atherosclerosis Research Institute, Department of Medical Sciences, McMaster University, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada
    Thromb Haemost 109:421-30. 2013
  5. doi request reprint New oral anticoagulants: which one should my patient use?
    Jeffrey I Weitz
    Department of Medicine, McMaster University, Hamilton, ON, Canda
    Hematology Am Soc Hematol Educ Program 2012:536-40. 2012
  6. ncbi request reprint Oral direct factor Xa inhibitors
    Calvin H Yeh
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Circ Res 111:1069-78. 2012
  7. ncbi request reprint New oral anticoagulants: a view from the laboratory
    Jeffrey I Weitz
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Am J Hematol 87:S133-6. 2012
  8. pmc New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Jeffrey I Weitz
    Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 141:e120S-51S. 2012
  9. doi request reprint Potential of new anticoagulants in patients with cancer
    Jeffrey I Weitz
    Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Henderson Research Centre, Ontario, Canada
    Thromb Res 125:S30-5. 2010
  10. doi request reprint Factor Xa and thrombin as targets for new oral anticoagulants
    Jeffrey I Weitz
    Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Thromb Res 127:S5-S12. 2011

Collaborators

Detail Information

Publications75

  1. ncbi request reprint New anticoagulants for treatment of venous thromboembolism
    Peter L Gross
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arterioscler Thromb Vasc Biol 28:380-6. 2008
    ....
  2. ncbi request reprint Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
    Jeffrey I Weitz
    Thrombosis and Atherosclerosis Research Institute, Hamilton General Hospital, Ontario, Canada
    Thromb Haemost 104:633-41. 2010
    ..In contrast, the edoxaban bid regimens were associated with more bleeding than warfarin. These results suggest that in this three-month study, edoxaban 30 or 60 mg qd are safe and well-tolerated...
  3. ncbi request reprint Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits
    J W Yau
    Dr Jeffrey I Weitz, Thrombosis and Atherosclerosis Research Institute, David Braley Research Institute, 237 Barton St E, Hamilton, ON L8L2X2, Canada, Tel 1 905 574 8550, Fax 1 905 575 2646, E mail
    Thromb Haemost 112:79-86. 2014
    ..7-fold. These findings suggest that only peak levels of dabigatran are sufficient to prevent catheter-induced clotting unless supplemented heparin is given. ..
  4. doi request reprint Zinc: an important cofactor in haemostasis and thrombosis
    Trang T Vu
    Thrombosis and Atherosclerosis Research Institute, Department of Medical Sciences, McMaster University, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada
    Thromb Haemost 109:421-30. 2013
    ..This paper reviews the mechanisms by which zinc regulates coagulation, platelet aggregation, anticoagulation and fibrinolysis and outlines how zinc serves as a ubiquitous modulator of haemostasis and thrombosis...
  5. doi request reprint New oral anticoagulants: which one should my patient use?
    Jeffrey I Weitz
    Department of Medicine, McMaster University, Hamilton, ON, Canda
    Hematology Am Soc Hematol Educ Program 2012:536-40. 2012
    ....
  6. ncbi request reprint Oral direct factor Xa inhibitors
    Calvin H Yeh
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Circ Res 111:1069-78. 2012
    ..Thus, the long path to finding replacements for warfarin has finally reached fruition. Therefore, development of the oral factor Xa inhibitors represents a translational science success story...
  7. ncbi request reprint New oral anticoagulants: a view from the laboratory
    Jeffrey I Weitz
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Am J Hematol 87:S133-6. 2012
    ....
  8. pmc New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Jeffrey I Weitz
    Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 141:e120S-51S. 2012
    ....
  9. doi request reprint Potential of new anticoagulants in patients with cancer
    Jeffrey I Weitz
    Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Henderson Research Centre, Ontario, Canada
    Thromb Res 125:S30-5. 2010
    ..In the coming years, these drugs are likely to replace warfarin for most indications. This paper addresses their potential role for prevention and treatment of cancer-related thrombosis...
  10. doi request reprint Factor Xa and thrombin as targets for new oral anticoagulants
    Jeffrey I Weitz
    Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Thromb Res 127:S5-S12. 2011
    ..The new agents produce such a predictable anticoagulant response that they can be given in fixed doses without monitoring. This paper focuses on the new oral anticoagulants in the most advanced stages of development...
  11. doi request reprint A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery
    Jeffrey I Weitz
    Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 104:1150-7. 2010
    ..All TAK-442 doses except 10 and 20 mg BID displayed similar efficacy and safety profiles to enoxaparin...
  12. ncbi request reprint New anticoagulants
    J I Weitz
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 3:1843-53. 2005
    ..After a brief review of coagulation pathways, this paper focuses on new anticoagulants in advanced stages of clinical testing...
  13. ncbi request reprint Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results
    S S Anand
    From the Preventive Cardiology and Therapeutics Program, Hamilton Civics Hospital Research Centre, and Division of Cardiology, McMaster University, Hamilton, Canada
    Circulation 98:1064-70. 1998
    ..We studied the effects of long-term warfarin at 2 intensities in patients with AIS without ST elevation in 2 consecutive randomized controlled studies...
  14. ncbi request reprint Vasoflux, a new anticoagulant with a novel mechanism of action
    J I Weitz
    Hamilton Civic Hospitals Reseach Centre, Hamilton, Ontario, Canada
    Circulation 99:682-9. 1999
    ..Heparin does not inactivate fibrin-bound thrombin, whereas hirudin fails to block thrombin generation. In contrast, Vasoflux is a novel anticoagulant that inactivates fibrin-bound thrombin and attenuates factor Xa generation...
  15. ncbi request reprint Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction
    J I Weitz
    Department of Medicine, McMaster University, Hamilton Civic Hospital Research Center, Ontario, Canada
    Arch Intern Med 160:749-58. 2000
    ..We focus on the opportunities presented by these agents, detailing mechanisms of action, advantages over aspirin and heparin, and performance in recent clinical trials...
  16. ncbi request reprint Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase
    J A Anderson
    Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 276:9755-61. 2001
    ..These studies reveal that sLA-LMWH acts as a potent antithrombin-independent inhibitor of coagulation by attenuating intrinsic tenase and prothrombinase...
  17. ncbi request reprint Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis
    A Y Lee
    McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 131:417-23. 1999
    ..Although D-dimer assays have high negative predictive values for the diagnosis of deep venous thrombosis, their accuracy in patients with cancer is uncertain...
  18. ncbi request reprint Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin
    T J Podor
    Department of Pathology and Molecular Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 275:19788-94. 2000
    ..These findings indicate that plasma PAI-1.vitronectin complexes can be localized to the surface of fibrin clots; by this localization, they may modulate fibrinolysis and clot reorganization...
  19. ncbi request reprint Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study
    M A Crowther
    Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada
    Thromb Haemost 85:390-4. 2001
    ..Our study also confirms that patients with idiopathic venous thromboembolism have a high risk of recurrence...
  20. ncbi request reprint Heparin compromises streptokinase-induced arterial patency in rabbits
    M Vlasin
    Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
    Thromb Res 115:427-34. 2005
    ..In this study, we compared the effects of unfractionated heparin (UH), low-molecular weight heparin (LMWH), and recombinant desulfohirudin (HIR) in combination with streptokinase (SK) in such settings...
  21. ncbi request reprint Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin
    S M Bates
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arch Intern Med 161:385-91. 2001
    ..We sought to identify an aPTT ratio that corresponds to therapeutic anti--factor Xa heparin levels for combinations of several reagents and coagulometers that are commonly used...
  22. ncbi request reprint Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin
    P C Liaw
    McMaster University and the Henderson Research Centre, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 276:20959-65. 2001
    ..Consequently, thrombin remains susceptible to inactivation by heparin cofactor II. This study explains why fibrin-bound thrombin is susceptible to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin...
  23. ncbi request reprint Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study
    J W Eikelboom
    Preventive Cardiology and Therapeutics Program, McMaster University, Hamilton, Canada
    Circulation 103:643-50. 2001
    ..The excess of major bleeding in hirudin-treated patients who develop thrombocytopenia suggests that thrombocytopenia may contribute to the increased risk of bleeding observed with hirudin...
  24. ncbi request reprint Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin
    A Y Lee
    Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Ontario, Canada
    Thromb Haemost 85:502-8. 2001
    ..This provides a mechanism to limit the concentration of (DD)E and maintain the fibrin-specificity of t-PA...
  25. ncbi request reprint Conformational changes in thrombin when complexed by serpins
    J C Fredenburgh
    Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 276:44828-34. 2001
    ..The disorganization of exosite 1 that occurs when thrombin is complexed by serpins is consistent with results of protease sensitivity studies and crystallographic analysis of a homologous enzyme-serpin complex...
  26. ncbi request reprint The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model
    P Klement
    McMaster University and Henderson Research Center, Hamilton, Ontario, Canada
    J Thromb Haemost 1:587-94. 2003
    ..Thus, at maximally effective doses, melagatran causes less bleeding than hirudin in this model. These findings raise the possibility that some direct thrombin inhibitors are safer than others...
  27. doi request reprint New antithrombotic drugs
    P L Gross
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Clin Pharmacol Ther 86:139-46. 2009
    ..This paper focuses on these new targets and new antiplatelet drugs and anticoagulants and describes the major advances in the continuing search for more potent antithrombotic drugs that have limited effects on hemostasis...
  28. ncbi request reprint Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
    J I Weitz
    Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Ontario, Canada
    Circulation 97:544-52. 1998
    ..Thrombolytic therapy induces a procoagulant state characterized by elevated plasma levels of fibrinopeptide A (FPA), but the responsible mechanism is uncertain...
  29. ncbi request reprint New oral anticoagulants in development
    Jeffrey I Weitz
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Thromb Haemost 103:62-70. 2010
    ..This paper focuses on the new oral anticoagulants in the most advanced stages of development...
  30. ncbi request reprint New anticoagulant drugs
    J I Weitz
    Hamilton Civic Hospitals Research Center and McMaster University, Hamilton, Ontario L8V 1C3, Canada
    J Thromb Thrombolysis 12:7-17. 2001
    ..This paper (1) reviews arterial and venous thrombogenesis, (2) outlines new anticoagulant strategies, and (3) provides clinical perspectives on these new strategies...
  31. ncbi request reprint Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
    C Kearon
    McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 2:743-9. 2004
    ..Retrospective analyses suggest that 1 month of anticoagulation is adequate for patients whose venous thromboembolic event was provoked by a transient risk factor...
  32. doi request reprint Meeting the unmet needs in anticoagulant therapy
    Jeffrey I Weitz
    Thrombosis and Atherosclerosis Research Institute, Hamilton General Hospital, Hamilton, ON, Canada
    Eur J Haematol 85:p1-28. 2010
    ..Designed to be given in fixed doses without routine anticoagulation monitoring, these new agents have the potential to revolutionize long-term anticoagulation therapy...
  33. doi request reprint Selective factor Xa inhibition for thromboprophylaxis
    John W Eikelboom
    McMaster University, Hamilton, ON, Canada
    Lancet 372:6-8. 2008
  34. ncbi request reprint Coagulation assays
    Shannon M Bates
    Department of Medicine, McMaster University, Henderson Research Centre, Hamilton, Ontario, Canada
    Circulation 112:e53-60. 2005
  35. doi request reprint Unanswered questions in venous thromboembolism
    Jeffrey I Weitz
    Departments of Medicine and Biochemistry, McMaster University, Henderson Research Centre, Hamilton, Ontario, Canada
    Thromb Res 123:S2-S10. 2009
    ..In addition, the new agents have the potential to streamline extended VTE therapy because, unlike vitamin K antagonists, they can be given in fixed doses without the need for coagulation monitoring...
  36. ncbi request reprint New anticoagulants
    Lori Ann Linkins
    Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 29:619-31. 2003
    ....
  37. ncbi request reprint Factor Xa or thrombin: is thrombin a better target?
    J I Weitz
    Henderson Research Centre and McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 5:65-7. 2007
    ..Several oral factor Xa inhibitors also are being tested. Is thrombin a better target for new oral anticoagulants than factor Xa? Only time will tell!..
  38. ncbi request reprint New anticoagulant therapy
    Lori Ann Linkins
    McMaster University and Henderson Research Center, Hamilton, Ontario, Canada L8V 1C3
    Annu Rev Med 56:63-77. 2005
    ..This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants...
  39. ncbi request reprint Emerging anticoagulants for the treatment of venous thromboembolism
    Jeffrey I Weitz
    Department of Medicine, McMaster University, Hamiton, Ontario, Canada
    Thromb Haemost 96:274-84. 2006
    ....
  40. doi request reprint Update on heparin: what do we need to know?
    Daniel S Weitz
    Department of Medicine, McMaster University, and Henderson Research Centre, Hamilton, ON, Canada
    J Thromb Thrombolysis 29:199-207. 2010
    ....
  41. ncbi request reprint Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial
    Shamir R Mehta
    McMaster University and the Population Health Research Institute, Hamilton Health Sciences, General Division, 237 Barton St E, Hamilton, Ontario, Canada L6K 1B8
    Circulation 111:1390-7. 2005
    ..We performed a randomized trial to determine the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting...
  42. ncbi request reprint New anticoagulants: an update
    Mark Crowther
    Division of Hematology, St Joseph s Hospital, McMaster University, Hamilton, Ontario, Canada
    Clin Adv Hematol Oncol 2:743-9. 2004
    ....
  43. ncbi request reprint Beyond heparin and warfarin: the new generation of anticoagulants
    Jeffrey I Weitz
    McMaster University and Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada
    Expert Opin Investig Drugs 16:271-82. 2007
    ....
  44. ncbi request reprint Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models
    N Vaezzadeh
    Dr Peter L Gross, Thrombosis and Atherosclerosis Research Institute, 237 Barton St East, Hamilton, Ontario, L8L 2X2 Canada, E mail
    Thromb Haemost 112:412-8. 2014
    ..In conclusion, venous, arterial and tail bleeding models are similarly affected by impaired coagulation, while platelet function defects have a greater influence in models incorporating arterial injury. ..
  45. ncbi request reprint A Protease TAMER: a nucleic acid-based anticoagulant
    J C Fredenburgh
    Departments of Medicine and Biochemistry and Biomedical Sciences and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 10:867-9. 2012
    ..See also Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. This issue, pp 870-80...
  46. ncbi request reprint Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage
    R C Austin
    Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 273:30808-17. 1998
    ..Furthermore, our findings suggest that intracellular glutathione and heat shock proteins play a role in protecting mitochondria against the adverse effects elicited by homocysteine and H2O2...
  47. ncbi request reprint Changing paradigms in the management of venous thromboembolism
    Jeffrey I Weitz
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Am Heart Hosp J 4:135-41. 2006
  48. ncbi request reprint New anticoagulants for treatment of venous thromboembolism
    Jeffrey I Weitz
    McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Circulation 110:I19-26. 2004
    ..The lack of an antidote for these new agents is a drawback, particularly for idraparinux, which has a long half-life...
  49. ncbi request reprint New anticoagulants: current status and future potential
    Jeffrey I Weitz
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Am J Cardiovasc Drugs 3:201-9. 2003
    ....
  50. pmc New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin
    Shannon M Bates
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Br J Pharmacol 144:1017-28. 2005
    ..After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing...
  51. ncbi request reprint In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation
    Lori Ann Linkins
    Henderson Research Centre and McMaster University, 711 Concession Street, Hamilton, Ontario, Canada L8V 1C3
    Thromb Res 107:241-4. 2002
    ..The ACT and aPTT therefore cannot be used to monitor low-molecular weight heparin or fondaparinux, highlighting the need for a point-of-care anti-factor Xa assay...
  52. ncbi request reprint Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin
    James C Fredenburgh
    Henderson Research Centre, Hamilton, Ontario, Canada
    Trends Cardiovasc Med 12:281-7. 2002
    ..In a rabbit carotid artery thrombosis prevention model, sLA-LMWH is superior to LMWH. Because of its low affinity for antithrombin and multiple sites of action, sLA-LMWH may prove to be safer and more effective than other anticoagulants...
  53. ncbi request reprint Direct thrombin inhibitors in acute coronary syndromes: present and future
    Jeffrey I Weitz
    McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Circulation 105:1004-11. 2002
  54. ncbi request reprint Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin
    Amy V L Schaefer
    Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
    Biochemistry 45:4257-65. 2006
    ..These data suggest that structural changes resulting from incorporation of fragment X into clots promote their lysis. Thus, attenuation of thrombolytic therapy-induced fragment X formation may reduce the risk of bleeding...
  55. ncbi request reprint Acute coronary syndromes: a focus on thrombin
    Jeffrey I Weitz
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    J Invasive Cardiol 14:2B-7B. 2002
  56. ncbi request reprint Direct thrombin inhibitors
    Jeffrey I Weitz
    McMaster University and Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3
    Thromb Res 106:V275-84. 2002
    ..This review summarizes the clinical trial data with direct thrombin inhibitors and provides perspective on the role of direct thrombin inhibitors in the face of other new anticoagulants currently under development...
  57. ncbi request reprint HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions
    Colin A Kretz
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Thromb Haemost 103:83-93. 2010
    ..These findings identify prothrombin as a potential target for new anticoagulants...
  58. ncbi request reprint Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide
    Ericka M Wiebe
    Henderson Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 278:35767-74. 2003
    ..IXa. Furthermore, our data suggest that the efficacy of pentasaccharide for prevention and treatment of thrombotic disorders may reflect its action at two sites in the coagulation system...
  59. ncbi request reprint A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis
    Shannon M Bates
    McMaster University Medical Centre, HSC 3W11, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
    Ann Intern Med 138:787-94. 2003
    ..Because clinical diagnosis is inaccurate, objective testing is usually considered necessary when patients present with suspected deep venous thrombosis (DVT)...
  60. ncbi request reprint Emerging anticoagulant drugs
    Shannon M Bates
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arterioscler Thromb Vasc Biol 23:1491-500. 2003
    ..After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing...
  61. ncbi request reprint Glycosaminoglycans bind factor Xa in a Ca2+-dependent fashion and modulate its catalytic activity
    Lee A O'Brien
    Henderson Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada
    Biochemistry 42:13091-8. 2003
    ..These studies suggest that glycosaminoglycan binding perturbs exosites on the surface of factor Xa, potentially modifying interactions with cofactors or substrates...
  62. ncbi request reprint An update on new anticoagulants
    Lori Ann Linkins
    McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada L8V 1C3
    Curr Drug Targets Cardiovasc Haematol Disord 3:287-300. 2003
    ....
  63. ncbi request reprint Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis
    Xufang Bai
    Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 102:1212-8. 2009
    ..Thus, fibrin loss from microarteriolar thrombi is mediated, at least in part, by leukocyte-associated uPA in a process that requires leukocyte uPAR and PSGL-1...
  64. ncbi request reprint An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial
    Clive Kearon
    McMaster University and the Henderson Research Centre, Hamilton, Ontario, Canada
    Ann Intern Med 144:812-21. 2006
    ..It may be safe to omit additional diagnostic testing in selected patients with suspected pulmonary embolism (PE) who have a negative D-dimer test, but this approach has never been evaluated in a randomized, controlled trial...
  65. ncbi request reprint Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy
    Joanne L Yu
    Henderson Research Centre, Experimental Thrombosis Research, McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 30:21-30. 2004
    ..Therefore, direct targeting of TF in cancer should be considered in combination with other treatment modalities such as oncogene-directed therapies, antiangiogenic agents (e.g., VEGF antagonists), and anti-cancer chemotherapy...
  66. ncbi request reprint Pharmacology and clinical potential of direct thrombin inhibitors
    Lori Ann Linkins
    McMaster University and Henderson Research Centre, Hamilton, Ontario, L8V 1C3, Canada
    Curr Pharm Des 11:3877-84. 2005
    ....
  67. ncbi request reprint Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex
    James C Fredenburgh
    Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
    J Biol Chem 283:2470-7. 2008
    ..Thus, bivalent binding of thrombin to gamma(A)/gamma'-fibrin protects thrombin from inhibition, raising the possibility that gamma(A)/gamma'-fibrin serves as a reservoir of active thrombin that renders thrombi thrombogenic...
  68. ncbi request reprint Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation
    Martin O'Donnell
    Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
    Am J Manag Care 10:S72-82. 2004
    ....
  69. ncbi request reprint Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh
    Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:141S-159S. 2008
    ..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients...
  70. ncbi request reprint Ximelagatran: the first oral direct thrombin inhibitor
    Mark A Crowther
    McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Expert Opin Investig Drugs 13:403-13. 2004
    ..It will also review the pharmacology of ximelagatran, discuss the clinical trial results with ximelagatran and provide perspective on the advantages and potential limitations of ximelagatran...
  71. doi request reprint Inhibition of osteolytic bone metastasis by unfractionated heparin
    Colin K Yee
    Department of Pathology and Molecular Medicine, McMaster University and the Henderson Research Center, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3
    Clin Exp Metastasis 25:903-11. 2008
    ..Based on these observations, we conclude that heparin inhibits the ability of tumour cells to metastasize to bone and that as such, prevents tumour cell-induced decreases in bone strength...
  72. ncbi request reprint Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation
    Samira B Jeimy
    Department of Pathology and Molecular Medicine, Health Sciences Center, McMaster University, 1200 Main St West, Hamilton, Ontario, Canada, L8N 3Z5
    Thromb Haemost 100:1058-67. 2008
    ..The high affinity binding of FV to MMRN1 may facilitate the costorage of the two proteins in platelet alpha-granules. As a consequence, MMRN1 release during platelet activation may limit platelet dependent thrombin generation in vivo...
  73. ncbi request reprint New anticoagulants
    Jack Hirsh
    Henderson Research Center, and McMaster University, Hamilton, Ontario, Canada
    Blood 105:453-63. 2005
    ..Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed...
  74. ncbi request reprint New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jeffrey I Weitz
    Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
    Chest 126:265S-286S. 2004
    ....
  75. ncbi request reprint Prevention and treatment of venous thromboembolism during pregnancy
    Jeffrey I Weitz
    Medicine and Biochemistry, McMaster University, 711 Concession Street, Hamilton, Ontario, Canada
    Catheter Cardiovasc Interv 74:S22-6. 2009
    ..Randomized clinical trials are needed to identify the optimal strategies for prevention and treatment of VTE in pregnancy...